Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome

References

• Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–2749.
   PubMed Web of Science ®Google Scholar
• Lindholm A, Andersson L, Eliasson M, Bixo M, Sundstrom-Poromaa I. Prevalence of symptoms associated with polycystic ovary syndrome. Int J Gynaecol Obstet 2008;102:39–43.
   PubMed Web of Science ®Google Scholar
• Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1357–1363.
   PubMed Web of Science ®Google Scholar
• Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, Dionyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2740–2746.
   PubMed Web of Science ®Google Scholar
• Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:6061–6067.
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4588–4593.
   PubMed Web of Science ®Google Scholar
• Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, Lombardi G, Rini GB, Lobo RA. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006;119:356 e1–356 e6.
   PubMed Web of Science ®Google Scholar
• Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P. Internal carotid-artery response to 5% carbon dioxide in women with polycystic ovaries. Lancet 2000;356:1166–1167.
   PubMed Web of Science ®Google Scholar
• Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P. Internal carotid artery haemodynamics in women with polycystic ovaries. Clin Sci (Lond) 2000;98:661–665.
   PubMedGoogle Scholar
• Lakhani K, Seifalian AM, Hardiman P. Impaired carotid viscoelastic properties in women with polycystic ovaries. Circulation 2002;106:81–85.
   PubMed Web of Science ®Google Scholar
• Macut D, Micic D, Cvijovic G, Sumarac M, Kendereski A, Zoric S, Pejkovic D. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 2001;14:1353–1359; discussion 1365.
   PubMedGoogle Scholar
• Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci 2006;1092:175–186.
   PubMed Web of Science ®Google Scholar
• Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006;185:227–239.
   PubMed Web of Science ®Google Scholar
• Talbott EO, Zborowskii JV, Boudraux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol 2004;56:27–39.
   PubMedGoogle Scholar
• Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000;3:101–105.
   PubMedGoogle Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595–600.
   PubMed Web of Science ®Google Scholar
• Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241–2247.
   PubMed Web of Science ®Google Scholar
• Nilsson T WP. The fibrinolytic system: biochemistry and assay methods. In: Nilsson T BK, Jansson J, editors, Clinical aspects of fibrinolysis. Almqvist & Wiksell; 1991. pp 9–54.
   Google Scholar
• Jansson JH, Nilsson TK, Johnson O. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 1998;80:334–337.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Bernardinelli L, Foco L, Galli M, Ribichini F, Tubaro M, Peyvandi F. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. J Thromb Haemost 2005;3:280–286.
   PubMedGoogle Scholar
• Orio F Jr, Palomba S, Cascella T, Tauchmanova L, Nardo LG, Di Biase S, Labella D, Russo T, Savastano S, Tolino A, et al Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online 2004;9:505–510.
   PubMed Web of Science ®Google Scholar
• Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996;45:623–629.
   PubMed Web of Science ®Google Scholar
• Tarkun I, Canturk Z, Arslan BC, Turemen E, Tarkun P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 2004;51:467–472.
   PubMedGoogle Scholar
• Atiomo WU, Fox R, Condon JE, Shaw S, Friend J, Prentice AG, Wilkin TJ. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000;52:487–492.
   PubMedGoogle Scholar
• Slopien R, Lewandowski K, Kolacz E, Zawilska K, Warenik-Szymankiewicz A. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. Gynecol Endocrinol 2006;22:651–654.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004;150:793–798.
   PubMed Web of Science ®Google Scholar
• Kelly CJ, Lyall H, Petrie JR, Gould GW, Connell JM, Rumley A, Lowe GD, Sattar N. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002;87:3287–3290.
   PubMedGoogle Scholar
• Lin S, Yongmei G. Plasminogen activator and plasma activator inhibitor-1 in young women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008;100:285–286.
   PubMedGoogle Scholar
• Sills ES, Drews CD, Perloe M, Tucker MJ, Kaplan CR, Palermo GD. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system. Gynecol Endocrinol 2003;17:231–237.
   PubMedGoogle Scholar
• Carmassi F, De Negri F, Fioriti R, De Giorgi A, Giannarelli C, Fruzzetti F, Pedrinelli R, Dell'Omo G, Bersi C. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res 2005;116:207–214.
   PubMed Web of Science ®Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Fertil Steril 2004;81:19–25.
   PubMed Web of Science ®Google Scholar
• Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 1992. pp 377–384.
   Google Scholar
• Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991;8:336–351.
   PubMed Web of Science ®Google Scholar
• Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511–516.
   PubMed Web of Science ®Google Scholar